BPC-157 + TB-500

What is BPC-157 + TB-500?

This is the higher-mass presentation of the pre-blended format, a single lyophilised vial co-formulated with BPC-157 10mg and TB-500 10mg, 20mg of total peptide under batch UKPL-9514. The two components are the same chemistry as the 5+5mg rung. BPC-157 is the pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.53 g/mol, CAS 137525-51-0. TB-500 is the synthetic 17-23 fragment of thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, molecular weight 4963.4 g/mol, CAS 77591-33-4. The individual mechanisms and literatures are covered on the separate BPC-157 and TB-500 product pages; this page documents the blend as a format and the 10+10mg presentation specifically. What the higher-mass rung changes is procedural: the molar ratio is untouched by doubling the mass, the number of reconstitution events and lot boundaries falls, and the honest position that no controlled study has evaluated this specific combination is unchanged. Supplied as lyophilised powder for in-vitro research use only, not a licensed medicine.

10+10mg vs 5+5mg: What the Rung Changes

Nothing chemical distinguishes the two rungs. The sequences, masses and ratio are identical, and 10mg plus 10mg is still equal by mass and roughly 3.5 to 1 by moles in favour of BPC-157, because doubling both masses scales moles in step. What differs is procedural. The 10+10mg vial delivers twice the peptide per reconstitution event, so a study needing a given total mass uses half the vials, half the diluent transfers and one lot boundary instead of two, and it supports either double the working concentration at a fixed fill volume or double the volume at a fixed concentration. The costs sit on the other side of the scale. Once reconstituted, 20mg is committed to a single in-use window, which is wasteful for low-throughput designs that would otherwise spread the same mass across two staggered reconstitutions, and a handling error at reconstitution destroys twice the material. Analytically, the certificate must resolve two species of very different mass in either rung, though the larger absolute masses in the 10+10mg vial put marginally more signal behind the assay of each component.

BPC-157 + TB-500 Research Applications

The 10+10mg presentation suits preclinical soft-tissue and cell-migration designs whose timelines or cell numbers consume more peptide than a 5+5mg vial supplies: long-duration explant and co-culture experiments, concentration-response matrices, and designs that must hold one lot across every arm. The underlying literatures remain separate and preclinical for musculoskeletal endpoints. BPC-157 work centres on local angiogenic signalling, with Hsieh and colleagues (J Mol Med, 2017) reporting VEGFR2 upregulation and internalisation in human endothelial cells, and Chang and colleagues (J Appl Physiol, 2011) reporting increased focal adhesion kinase and paxillin phosphorylation in cultured rat tendon fibroblasts. Thymosin beta-4 work centres on actin binding and cell migration, with Bock-Marquette and colleagues (Nature, 2004) reporting cell migration and survival effects in mouse cardiac injury models and Philp and colleagues (Wound Repair Regen, 2003) reporting that the synthetic actin-binding domain peptide LKKTETQ promoted dermal wound repair in diabetic and aged mice. No controlled study has tested the two in combination against either alone, and a 2025 review by McGuire and colleagues (Curr Rev Musculoskelet Med) identified only three human pilot studies for BPC-157, with no adequately powered randomised controlled trials.

Reconstitution Guide

Treat the vial as a single 20mg preparation, with one fill volume set by the concentration your protocol specifies. Allow the vial and the bacteriostatic water to reach room temperature, swab both rubber stoppers with alcohol, then inject the diluent slowly down the inner glass wall rather than onto the lyophilised cake, and swirl gently until fully dissolved. Never shake or vortex: the TB-500 chain is shear sensitive and agitation reduces recovery of intact peptide, and the larger 20mg cake can take slightly longer to dissolve completely, so wait for a fully clear, colourless solution before drawing. Two points are specific to the blended format. First, the components cannot be separated after reconstitution, so protocols needing an independently chosen ratio require separate vials. Second, when expressing the preparation in molar terms, the components are present at roughly 7.0 µmol and 2.0 µmol respectively, not in equal molar amounts. Label the vial with the fill volume, resulting concentration and reconstitution date.

See our full peptide reconstitution guide and reconstitution calculator for step-by-step protocol.

Storage Instructions

Lyophilised vials should be stored at -20°C, protected from light and moisture, and remain stable for up to 24 months. Once reconstituted, hold the solution at 2-8°C and prepare single-use aliquots at -20°C for anything beyond short-term use. Because both components share one reconstitution date in a co-formulated vial, the shorter of the two in-use windows governs the whole preparation, and at 10+10mg that single window covers twice the peptide, so aliquot early rather than repeatedly accessing one stock. Avoid repeated freeze-thaw cycles, which reduce recovery of the TB-500 chain in particular, label every aliquot with the reconstitution date, and handle throughout under sterile laboratory conditions.

Frequently Asked Questions

Research References

• Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang et al., J Appl Physiol, 2011)
• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
• Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice (Philp et al., Wound Repair Regen, 2003)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., Curr Rev Musculoskelet Med, 2025)

Related Research Compounds

• → BPC-157 + TB-500 5+5mg (lower-mass presentation)
• → BPC-157 5mg (main product page)
• → TB-500 5mg (main product page)
• → Bacteriostatic Water 10ml